July 1, 2003
Warburg Pincus invests $25 million in Bacchus Vascular, Inc., a Delaware corporation focused on the discovery and development of innovative treatments for cardiovascular and peripheral vascular occlusive disease.
On July 1, Willkie represented Warburg Pincus Private Equity VIII, L.P. (as lead investor) in its $25 million investment in Bacchus Vascular, Inc., a Delaware corporation focused on the discovery and development of innovative treatments for cardiovascular and peripheral vascular occlusive disease. Newly created Series D Convertible Preferred Stock was purchased. The investment included initial $5.2 million bridge note and warrant financings, with the later conversion of such bridge notes and certain other notes into, together with an additional cash investment in, the equity of the company. The Daily Deal Online reported that the transaction was handled by partner Jeffrey Poss and associate Mark Getachew.
